TD Asset Management Inc Purchases 9,000 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

TD Asset Management Inc increased its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 5.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 173,679 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. TD Asset Management Inc’s holdings in Allogene Therapeutics were worth $1,092,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ALLO. Oppenheimer & Co. Inc. boosted its holdings in shares of Allogene Therapeutics by 24.9% during the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company’s stock worth $137,000 after buying an additional 3,000 shares during the period. AlphaCrest Capital Management LLC boosted its holdings in Allogene Therapeutics by 83.4% in the 1st quarter. AlphaCrest Capital Management LLC now owns 49,574 shares of the company’s stock valued at $452,000 after purchasing an additional 22,540 shares during the period. MetLife Investment Management LLC boosted its holdings in Allogene Therapeutics by 58.6% in the 1st quarter. MetLife Investment Management LLC now owns 36,326 shares of the company’s stock valued at $331,000 after purchasing an additional 13,419 shares during the period. BlackRock Inc. boosted its holdings in Allogene Therapeutics by 8.6% in the 1st quarter. BlackRock Inc. now owns 7,086,233 shares of the company’s stock valued at $64,557,000 after purchasing an additional 560,279 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Allogene Therapeutics by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 805,987 shares of the company’s stock valued at $7,344,000 after purchasing an additional 61,259 shares during the period. Institutional investors own 72.94% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ALLO. JPMorgan Chase & Co. raised shares of Allogene Therapeutics from a “neutral” rating to an “overweight” rating and cut their price objective for the company from $20.00 to $11.00 in a report on Tuesday, January 24th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Allogene Therapeutics in a research report on Thursday, April 20th. Truist Financial dropped their target price on shares of Allogene Therapeutics from $29.00 to $20.00 in a research report on Wednesday, March 1st. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research report on Wednesday, March 22nd. Finally, The Goldman Sachs Group dropped their target price on shares of Allogene Therapeutics from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.50.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $6.36 on Thursday. The firm’s fifty day moving average is $5.39 and its 200-day moving average is $7.05. Allogene Therapeutics, Inc. has a 52 week low of $4.42 and a 52 week high of $17.49. The firm has a market cap of $927.54 million, a P/E ratio of -2.61 and a beta of 0.77.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last posted its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05). The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.08 million. Allogene Therapeutics had a negative net margin of 150,207.69% and a negative return on equity of 50.21%. During the same period in the prior year, the company posted ($0.56) earnings per share. As a group, sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Allogene Therapeutics Profile

(Get Rating)

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.